查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1717199

阿茲海默症診斷與治療市場（按產品、患者族群、疾病階段、最終用戶和分銷管道）—2025-2030 年全球預測

Alzheimer's Disease Diagnostics & Therapeutics Market by Product, Patient Demographics, Disease Stage, End User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年阿茲海默症診斷和治療市場價值為 71.5 億美元，預計 2025 年將成長至 77.3 億美元，複合年成長率為 8.50%，預計到 2030 年將達到 116.6 億美元。

介紹

主要市場統計數據
基準年2024年 71.5億美元
預計2025年 77.3億美元
預測年份 2030 116.6億美元
複合年成長率（%） 8.50%

阿茲海默症持續對全球醫療保健構成重大挑戰，迫切需要創新的診斷和治療解決方案。在技​​術快速進步和對神經退化性疾病更深入了解的推動下，市場正在經歷重新定義臨床和研究軌蹟的變革。本報告全面介紹了推動診斷和治療突破性發展的新興趨勢、基於證據的見解和潛在的市場動態。當相關人員尋求平衡傳統方法與顛覆性創新時，了解科學發現與市場現實之間的策略相互作用至關重要。以下討論旨在為決策者提供一個細緻的視角，了解疾病檢測和管理中不斷發展的觀點如何為更個性化、高效和有影響力的患者照護奠定基礎。

透過整合最新的研究和市場分析，這項研究揭示了阿茲海默症治療的多層面，同時確定了有望重塑競爭格局的關鍵機會。這是一個探索技術、生物學和策略洞察力融合的邀請，在這個市場中，每項進步都有可能顯著改善患者的治療效果。

改變阿茲海默症診斷和藥物市場

阿茲海默症市場正在經歷變革時期徹底改變診斷和治療性介入的變革。科學突破加上不斷發展的法律規範加速了新型生物標記和影像技術的應用，使得診斷能夠在更早、更易於治療的階段檢測出疾病。同時，研究資金的激增以及研究機構之間的合作也促進了有前景的治療方案的出現。這些新治療方法不僅基於基因洞察，還利用基因編輯和細胞療法等先進的治療方法重新定義治療範式。

對研究重點進行策略性重新思考，加上提高對阿茲海默症社會影響的認知，將確保創新與以患者為中心的目標一致。同時，隨著資料收集和分析技術的進步推動精準醫療的發展，病患的人口結構也在改變。這種快速發展的環境要求市場相關人員必須適應，在嚴格的臨床檢驗需求和滿足不斷成長的患者期望需求之間取得平衡。隨著診斷和治療之間的界限變得越來越模糊，綜合護理模式正在出現，提供從早期檢測到有針對性的治療計劃的無縫過渡。

此外，數位健康和​​遠端監控的進步正在重塑患者管理，使臨床醫生能夠即時追蹤病情進展。這些轉變促使人們重新評估傳統的市場結構，並開啟跨學科創新與合作的時代。這一轉變的背後通用，即透過及時干預、客製化治療策略和強大的尖端解決方案來減輕阿茲海默症的負擔，這將決定神經退化性疾病管理的未來。

關鍵環節分析

阿茲海默症診斷和治療市場正變得越來越細緻入微，需要採用多方面的細分策略來深入了解機會和挑戰。在產品層面，診斷用藥和治療用藥分類明確。診斷技術已經發展到涵蓋一系列工具，包括生物標記、認知評估測試、基因檢測和先進的影像技術。具體來說，生物標記評估正在擴展到基於血液和基於腦脊髓液（CSF）的領域，為早期檢測和疾病進展監測提供了雙重方法。在治療方面，市場分為新興治療和成熟的藥物治療。新興療法以基因療法、單株抗體和幹細胞療法等創新療法為主導，而傳統藥理學方法則以膽鹼酯酶抑制劑和 NMDA 受體拮抗劑為基礎。

透過將市場細分為反映發病率和治療反應差異的年齡亞組，分析患者的人口統計數據可以提供進一步的見解。這包括對 65-74 歲、75-84 歲和 85 歲以上人群與 65 歲以下年輕群體進行比較的分析考慮。這些差異凸顯了根據不同年齡層固有的生理和代謝變化來制定治療方案的必要性。同時，分析疾病的階段至關重要，早期、中期和晚期阿茲海默症患者之間存在顯著差異。這種細分不僅為臨床決策提供資訊，而且還為根據疾病的病理學進展進行微調的有針對性的干涉策略鋪平了道路。

此外，按最終用戶進行細分可以揭示診斷和治療解決方案所部署的不同業務環境。家庭醫療保健機構正致力於整合遠端患者監護並讓居家照護護理人員參與其中，而醫院和診所則正在適應專門的老年病中心和神經科業務。包括學術和商業實驗室在內的研究機構繼續充當推動下一代臨床突破的創新中心。此外，還繪製了醫院、網路藥局和零售藥局的分銷管道，展示了不斷變化的患者偏好以及數位平台在藥品分銷中日益成長的作用。每一層細分都構成了整體情況，其特點是快速發展和適應性策略，以應對當前和未來的挑戰。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 全球老化人口中阿茲海默症的盛行率不斷上升
      • 引入基於生物標記的測試，以促進更早、更準確的診斷
      • 數位健康解決方案和穿戴式科技在阿茲海默症患者照護中的重要性日益增加
    • 限制因素
      • 開發和核准阿茲海默症藥物的成本高昂
    • 機會
      • 專門管理和支持阿茲海默症患者的居家照護服務的成長
      • 加大研發投入推動阿茲海默症治療取得新進展
    • 任務
      • 診斷標準缺乏標準化，導致阿茲海默症的診斷結果不一致。
  • 市場區隔分析
    • 產品：在阿茲海默症診斷中優先考慮血液生物標記物，有望實現廣泛的篩檢，而無需複雜的程序
    • 最終用戶：在老年中心採用阿茲海默症症治療和治療方法來滿足老年患者的複雜需求
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

第6章阿茲海默症診斷與治療市場（按產品）

  • 診斷
    • 生物標記
      • 血液中的生物標記
      • 腦脊髓液生物標記
    • 認知評估測試
    • 基因檢測
    • 影像技術
  • 治療
    • 新興療法
      • 基因治療
      • 單株抗體
      • 幹細胞療法
    • 藥物治療
      • 膽鹼酯酶抑制劑
      • NMDA受體拮抗劑

第7章阿茲海默症診斷與治療市場（按患者人口統計）

  • 65-74歲
  • 75-84歲
  • 85歲或以上
  • 65歲以下

第8章阿茲海默症診斷和治療藥物市場（按疾病階段）

  • 早期阿茲海默症
  • 晚期阿茲海默症
  • 中期阿茲海默症

第9章阿茲海默症診斷和治療藥物市場（按最終用戶）

  • 家庭醫療保健
    • 家庭護理服務提供者
    • 遠端患者監護
  • 醫院和診所
    • 老人中心
    • 神經科
  • 研究機構
    • 學術研究所
    • 私人研究機構

第 10 章阿茲海默症診斷和治療藥物市場（按分銷管道）

  • 醫院藥房
  • 網路藥局
  • 零售藥局

11.美國阿茲海默阿茲海默症診斷與治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

12.亞太地區阿茲海默症診斷與藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

13.歐洲、中東和非洲阿茲海默症診斷和治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • Abbvie Inc.
  • AC Immune SA
  • Alector, Inc.
  • Alzheon, Inc.
  • Amylyx Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • BioXcel Therapeutics Inc.
  • Bristol-Myers Squibb Company
  • Cognoptix Inc.
  • Corium Inc.
  • Denali Therapeutics Inc.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Grifols, SA
  • H. Lundbeck A/S
  • Lexeo Therapeutics, Inc.
  • Luye Pharma Group
  • Merz Pharma GmbH & Co. KGaA
  • MODAG GmbH
  • Muna Therapeutics
  • Novartis AG
  • Pfizer, Inc.
  • Siemens Healthineers AG
  • TauRx Therapeutics Ltd.
  • VectorY Therapeutics
  • Vigil Neuroscience, Inc.
  • Voyager Therapeutics, Inc.
  • Zydus Lifesciences Limited
Product Code: MRR-742BD517AA98

The Alzheimer's Disease Diagnostics & Therapeutics Market was valued at USD 7.15 billion in 2024 and is projected to grow to USD 7.73 billion in 2025, with a CAGR of 8.50%, reaching USD 11.66 billion by 2030.

Introduction

KEY MARKET STATISTICS
Base Year [2024] USD 7.15 billion
Estimated Year [2025] USD 7.73 billion
Forecast Year [2030] USD 11.66 billion
CAGR (%) 8.50%

Alzheimer's disease continues to pose profound challenges across global healthcare landscapes, driving an urgent need for innovative diagnostic and therapeutic solutions. In an era marked by rapid technological advances and a deeper understanding of neurodegenerative conditions, the market is witnessing an evolution that redefines both clinical practice and research trajectories. This report provides a comprehensive exploration of emerging trends, evidence-based insights, and the underlying market dynamics fueling groundbreaking developments in diagnostics and therapeutics. As stakeholders seek to balance traditional methodologies with disruptive innovations, it becomes essential to appreciate the strategic interplay between scientific discovery and market realities. The following discussion aims to furnish decision-makers with a nuanced perspective on how evolving paradigms in disease detection and management are setting the stage for more personalized, efficient, and impactful patient care.

By integrating the latest research with market analytics, this analysis unfolds the multifaceted layers of Alzheimer's disease interventions while identifying key opportunities that promise to reshape the competitive landscape. It is an invitation to explore the confluence of technology, biology, and strategic insight in a market where every advancement holds the potential to significantly improve patient outcomes.

Transformative Shifts in the Landscape

The Alzheimer's disease market is undergoing transformative shifts that are revolutionizing diagnostic practices and therapeutic interventions. A confluence of scientific breakthroughs and evolving regulatory frameworks has accelerated the introduction of novel biomarkers and imaging technologies, positioning diagnostics to detect the disease at earlier and more treatable stages. Concurrently, a surge in research funding and cross-institutional collaborations has fortified the pipeline of promising therapeutic options. These emerging therapies are not only built on a foundation of genetic insights but are also leveraging advanced modalities such as gene editing and cellular therapies to redefine treatment paradigms.

The strategic reframing of research priorities, coupled with enhanced awareness of the societal impact of Alzheimer's, ensures that innovations are aligned with patient-centric goals. In parallel, the dynamics of patient demographics are shifting, supported by improvements in data acquisition and analytics that facilitate precision medicine. This rapidly evolving environment demands adaptability from market players, as they balance the need for rigorous clinical validation with the imperative to meet escalating patient expectations. As the lines between diagnostics and therapeutics increasingly blur, integrated care models are emerging that offer seamless transitions from early detection to targeted treatment plans.

Moreover, advancements in digital health and remote monitoring are reshaping patient management, allowing clinicians to track disease progression in real-time. These shifts are now prompting a reevaluation of traditional market structures, sparking an era of interdisciplinary innovation and collaboration. Underpinning these changes is a shared commitment to reducing the burden of Alzheimer's disease through timely intervention, customized treatment strategies, and a robust pipeline of cutting-edge solutions that are set to define the future of neurodegenerative disease management.

Key Segmentation Insights

The market for Alzheimer's diagnostics and therapeutics has become increasingly nuanced, driven by multi-dimensional segmentation strategies that provide a granular understanding of opportunities and challenges. At the product level, the landscape has been distinctly divided between diagnostics and therapeutics. Diagnostics have evolved to encompass a range of tools including biomarkers, cognitive assessment tests, genetic testing, and advanced imaging techniques. In particular, biomarker assessment now extends into both blood-based and cerebrospinal fluid (CSF) domains, offering a dual approach to early detection and disease progression monitoring. On the therapeutics side, market stratification distinguishes between emerging therapeutics and established pharmacological treatments. Emerging therapies are spearheaded by innovations such as gene therapy, monoclonal antibodies, and stem cell therapy, while traditional pharmacological approaches continue to be anchored by cholinesterase inhibitors and NMDA receptor antagonists.

Insights extend further when analyzing patient demographics, which segment the market into age subgroups that reflect variations in incidence and treatment responsiveness. These include analytical considerations for individuals aged 65-74 years, 75-84 years, and above 85 years, as compared to younger cohorts under 65. Such distinctions underscore the need for treatments that are tailored to the physiological and metabolic variations intrinsic to different age groups. In parallel, analyzing the disease stage is pivotal, with significant differences noted among patients in early-stage, middle-stage, and late-stage Alzheimer's. This segmentation not only informs clinical decision-making but also paves the way for creating targeted intervention strategies that can be fine-tuned based on the pathophysiological progression of the disease.

Furthermore, segmentation by end user reveals the diverse operational environments where diagnostic and therapeutic solutions are deployed. Home healthcare settings have garnered attention through the integration of remote patient monitoring and the involvement of home care providers, while hospitals and clinics adapt their operations within specialized geriatric centers and neurology departments. Research institutes, encompassing both academic and private laboratories, continue to serve as innovation hubs that drive the next generation of clinical breakthroughs. Additionally, distribution channels have been mapped out across hospital, online, and retail pharmacies, indicating evolving patient preferences and the growing role of digital platforms in medication distribution. Each layer of segmentation contributes to a holistic picture of a market characterized by rapid evolution and adaptive strategies aimed at meeting both current and future challenges.

Based on Product, market is studied across Diagnostics and Therapeutics. The Diagnostics is further studied across Biomarkers, Cognitive Assessment Tests, Genetic Testing, and Imaging Techniques. The Biomarkers is further studied across Blood-Based Biomarkers and CSF Biomarkers. The Therapeutics is further studied across Emerging Therapeutics and Pharmacological Treatments. The Emerging Therapeutics is further studied across Gene Therapy, Monoclonal Antibodies, and Stem Cell Therapy. The Pharmacological Treatments is further studied across Cholinesterase Inhibitors and NMDA Receptor Antagonists.

Based on Patient Demographics, market is studied across 65-74 Years, 75-84 Years, Above 85 Years, and Below 65 Years.

Based on Disease Stage, market is studied across Early-Stage Alzheimer's, Late-Stage Alzheimer's, and Middle-Stage Alzheimer's.

Based on End User, market is studied across Home Healthcare, Hospitals & Clinics, and Research Institutes. The Home Healthcare is further studied across Home Care Providers and Remote Patient Monitoring. The Hospitals & Clinics is further studied across Geriatric Centers and Neurology Departments. The Research Institutes is further studied across Academic Research Institutes and Private Research Laboratories.

Based on Distribution Channel, market is studied across Hospital pharmacies, Online pharmacies, and Retail pharmacies.

Key Regional Insights

Geographical segmentation reveals that the market dynamics for Alzheimer's disease diagnostics and therapeutics vary considerably across regions. In the Americas, robust research infrastructures, combined with substantial government and private funding, are fueling innovations in both early diagnosis and personalized treatment approaches. The region's strong emphasis on preventive care and integrated health management provides a solid foundation for the adoption of advanced diagnostic tools.

In Europe, the Middle East, and Africa, a unique blend of regulatory environments and patient demographics is driving tailored strategies. European markets exhibit a high level of clinical collaboration and regulatory support, while emerging economies in the Middle East and Africa are rapidly adapting to newer technologies through strategic public-private partnerships. The interplay of extensive healthcare networks and innovative clinical trial initiatives in these regions is fostering a competitive spirit that challenges conventional treatment paradigms.

Asia-Pacific presents a dynamic and rapidly growing landscape. Characterized by significant investment in healthcare technology and a rising prevalence of neurodegenerative disorders, this region is at the forefront of embracing digital health solutions. The convergence of technological adoption, rising healthcare expenditure, and proactive government initiatives are contributing to an environment of accelerated growth and innovation. This regional heterogeneity underscores the importance of localized strategies that can effectively balance global best practices with the nuanced needs of distinct demographic and economic contexts.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights

A host of pioneering companies are actively reshaping the Alzheimer's diagnostics and therapeutics arena through a blend of strategic investments, innovative research, and robust market positioning. Industry leaders such as Abbvie Inc. and AC Immune SA have consistently demonstrated a commitment to advancing both diagnostic tools and therapeutic solutions, leveraging state-of-the-art technologies and expansive clinical networks. Companies like Alector, Inc. and Alzheon, Inc. have carved out distinctive niches by focusing on targeted molecular pathways, whereas firms such as Amylyx Pharmaceuticals, Inc. and AstraZeneca PLC are accelerating initiatives that encompass both early detection and intervention strategies.

This competitive milieu is further enriched by the contributions of organizations like Biogen Inc. and BioXcel Therapeutics Inc., which are successfully bridging the gap between laboratory research and clinical application. Established pharmaceutical giants like Bristol-Myers Squibb Company and Pfizer, Inc. are also central to this evolving narrative, investing heavily in both innovative therapeutics and comprehensive care models. Cognoptix Inc. and Corium Inc. further complement this diverse portfolio by introducing breakthrough diagnostic technologies. Additionally, companies such as Denali Therapeutics Inc. and Eisai Co., Ltd. are steadily advancing novel approaches that span early-stage diagnosis to the management of advanced symptoms.

Other notable contributors include Eli Lilly and Company, F. Hoffmann-La Roche AG, and Grifols, S.A., all of which are leveraging their global reach and technological prowess. H. Lundbeck A/S and Lexeo Therapeutics, Inc. are emerging leaders that underscore the role of niche strategies in a competitive landscape. The involvement of firms like Luye Pharma Group and Merz Pharma GmbH & Co. KGaA demonstrates a commitment to diversified product portfolios, while emerging entities such as MODAG GmbH and Muna Therapeutics continue to push the technological envelope. Companies including Novartis AG, Siemens Healthineers AG, TauRx Therapeutics Ltd., VectorY Therapeutics, Vigil Neuroscience, Inc., Voyager Therapeutics, Inc., and Zydus Lifesciences Limited together complete a vibrant ecosystem defined by relentless innovation and strategic foresight. Collectively, these organizations illustrate a dynamic blend of forward-thinking research, market adaptability, and a shared objective of mitigating the impact of Alzheimer's disease on global populations.

The report delves into recent significant developments in the Alzheimer's Disease Diagnostics & Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., AC Immune SA, Alector, Inc., Alzheon, Inc., Amylyx Pharmaceuticals, Inc., AstraZeneca PLC, Biogen Inc., BioXcel Therapeutics Inc., Bristol-Myers Squibb Company, Cognoptix Inc., Corium Inc., Denali Therapeutics Inc., Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, Grifols, S.A., H. Lundbeck A/S, Lexeo Therapeutics, Inc., Luye Pharma Group, Merz Pharma GmbH & Co. KGaA, MODAG GmbH, Muna Therapeutics, Novartis AG, Pfizer, Inc., Siemens Healthineers AG, TauRx Therapeutics Ltd., VectorY Therapeutics, Vigil Neuroscience, Inc., Voyager Therapeutics, Inc., and Zydus Lifesciences Limited. Actionable Recommendations for Industry Leaders

Industry leaders are advised to continuously monitor emerging trends and integrate flexible, adaptive strategies into their operational frameworks. Maintaining a forward-leaning perspective by investing in collaborative research ventures and advanced clinical trials is crucial. Profiles of traditional and innovative therapeutic solutions must coexist with a strong emphasis on real-world efficacy and patient-centric outcomes. Decision-makers should broaden their approaches by embracing digital health technologies, which not only drive cost efficiencies but also bolster patient management through remote monitoring and data analytics.

Strategic realignment toward personalized diagnostic platforms that utilize advanced biomarkers, genetic testing, and neuroimaging is essential to ensuring early disease detection and effective care planning. It is recommended that companies develop robust partnerships with academic research institutes and clinical centers to foster a more agile and responsive innovation ecosystem. Additionally, aligning product development with regulatory trends while anticipating changes in reimbursement policies will bolster market resilience.

Expanded investment in comprehensive patient segmentation studies can help tailor treatment modalities to distinct demographic and disease-stage profiles. This data-driven approach will empower market players to refine their portfolio strategies and optimize resource allocation. A commitment to leveraging local market insights, particularly across diverse regions such as the Americas, Europe, Middle East & Africa, and Asia-Pacific, will be a key driver in crafting region-specific strategies that capture both established opportunities and emerging niches. Embracing these recommendations will position industry leaders to not only navigate the current market volatility but also to sustainably drive future growth and innovation.

Conclusion

In summary, the Alzheimer's disease diagnostics and therapeutics landscape is marked by rapid innovation, evolving regulatory frameworks, and a diverse ecosystem of market players. The convergence of advanced diagnostic methodologies and cutting-edge therapeutic approaches presents a robust pathway for early detection and effective intervention, ultimately leading to enhanced patient outcomes. By embracing strategic segmentation that captures product nuances, patient demographics, disease stages, operational settings, and distribution channels, stakeholders can unlock value across multiple facets of the market.

The analysis underscores a clear trend: the integration of sophisticated biomarker analyses, genetic research, and neuroimaging technologies is transforming traditional paradigms. With an emphasis on personalized treatment plans that are tailored to the specific needs of diverse patient populations, the industry is poised for continued growth and evolution. Regional insights further highlight the need for adaptive strategies that leverage the unique strengths of various geographic markets. As companies innovate and compete on the global stage, the commitment to high-quality research and rigorous clinical validation remains paramount.

Ultimately, the report serves as a strategic guide that offers clear direction for exploiting market opportunities and mitigating risks in a rapidly changing environment. The comprehensive insights provided here are designed to arm stakeholders with the knowledge necessary to shape a resilient and forward-thinking market strategy that not only addresses current challenges but also unlocks future potential.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of Alzheimer's disease among the aging global population
      • 5.1.1.2. Introduction of biomarker-based tests facilitating early and accurate diagnosis
      • 5.1.1.3. Rising prominence of digital health solutions and wearable technology in Alzheimer's patient care
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with Alzheimer's disease drug development and approvals
    • 5.1.3. Opportunities
      • 5.1.3.1. Growth in home-based care services tailored for Alzheimer's patient management and support
      • 5.1.3.2. Increasing investments in research and development fuel new advancements in Alzheimer's therapeutics
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of standardization in diagnostic criteria contributes to inconsistent Alzheimer's diagnosis results
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Preference for blood based biomarker for alzheimer disease diagnostics to offer promise for widespread screening without the need for complex procedures
    • 5.2.2. End User: Adoption of Alzheimer disease treatment & therapeutics in geriatric centers to manage the complex needs of elderly patients
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Alzheimer's Disease Diagnostics & Therapeutics Market, by Product

  • 6.1. Introduction
  • 6.2. Diagnostics
    • 6.2.1. Biomarkers
      • 6.2.1.1. Blood-Based Biomarkers
      • 6.2.1.2. CSF Biomarkers
    • 6.2.2. Cognitive Assessment Tests
    • 6.2.3. Genetic Testing
    • 6.2.4. Imaging Techniques
  • 6.3. Therapeutics
    • 6.3.1. Emerging Therapeutics
      • 6.3.1.1. Gene Therapy
      • 6.3.1.2. Monoclonal Antibodies
      • 6.3.1.3. Stem Cell Therapy
    • 6.3.2. Pharmacological Treatments
      • 6.3.2.1. Cholinesterase Inhibitors
      • 6.3.2.2. NMDA Receptor Antagonists

7. Alzheimer's Disease Diagnostics & Therapeutics Market, by Patient Demographics

  • 7.1. Introduction
  • 7.2. 65-74 Years
  • 7.3. 75-84 Years
  • 7.4. Above 85 Years
  • 7.5. Below 65 Years

8. Alzheimer's Disease Diagnostics & Therapeutics Market, by Disease Stage

  • 8.1. Introduction
  • 8.2. Early-Stage Alzheimer's
  • 8.3. Late-Stage Alzheimer's
  • 8.4. Middle-Stage Alzheimer's

9. Alzheimer's Disease Diagnostics & Therapeutics Market, by End User

  • 9.1. Introduction
  • 9.2. Home Healthcare
    • 9.2.1. Home Care Providers
    • 9.2.2. Remote Patient Monitoring
  • 9.3. Hospitals & Clinics
    • 9.3.1. Geriatric Centers
    • 9.3.2. Neurology Departments
  • 9.4. Research Institutes
    • 9.4.1. Academic Research Institutes
    • 9.4.2. Private Research Laboratories

10. Alzheimer's Disease Diagnostics & Therapeutics Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital pharmacies
  • 10.3. Online pharmacies
  • 10.4. Retail pharmacies

11. Americas Alzheimer's Disease Diagnostics & Therapeutics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Alzheimer's Disease Diagnostics & Therapeutics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Alzheimer's Disease Diagnostics & Therapeutics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. AbbVie acquires Aliada Therapeutics to enhance Alzheimer's Disease research and innovations
    • 14.3.2. Eisai invests in C2N to enhance early Alzheimer's Disease diagnosis and treatment
    • 14.3.3. IHI launches interdisciplinary initiative to transform Alzheimer's Disease diagnosis and treatment
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbvie Inc.
  • 2. AC Immune SA
  • 3. Alector, Inc.
  • 4. Alzheon, Inc.
  • 5. Amylyx Pharmaceuticals, Inc.
  • 6. AstraZeneca PLC
  • 7. Biogen Inc.
  • 8. BioXcel Therapeutics Inc.
  • 9. Bristol-Myers Squibb Company
  • 10. Cognoptix Inc.
  • 11. Corium Inc.
  • 12. Denali Therapeutics Inc.
  • 13. Eisai Co., Ltd.
  • 14. Eli Lilly and Company
  • 15. F. Hoffmann-La Roche AG
  • 16. Grifols, S.A.
  • 17. H. Lundbeck A/S
  • 18. Lexeo Therapeutics, Inc.
  • 19. Luye Pharma Group
  • 20. Merz Pharma GmbH & Co. KGaA
  • 21. MODAG GmbH
  • 22. Muna Therapeutics
  • 23. Novartis AG
  • 24. Pfizer, Inc.
  • 25. Siemens Healthineers AG
  • 26. TauRx Therapeutics Ltd.
  • 27. VectorY Therapeutics
  • 28. Vigil Neuroscience, Inc.
  • 29. Voyager Therapeutics, Inc.
  • 30. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET MULTI-CURRENCY
  • FIGURE 2. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET MULTI-LANGUAGE
  • FIGURE 3. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 4. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 21. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 27. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD-BASED BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CSF BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COGNITIVE ASSESSMENT TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGING THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGING THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY 65-74 YEARS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY 75-84 YEARS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ABOVE 85 YEARS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BELOW 65 YEARS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EARLY-STAGE ALZHEIMER'S, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LATE-STAGE ALZHEIMER'S, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MIDDLE-STAGE ALZHEIMER'S, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME CARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REMOTE PATIENT MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GERIATRIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROLOGY DEPARTMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRIVATE RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGING THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGING THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 79. ARGENTINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 80. ARGENTINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGING THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 88. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 89. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
  • TABLE 91. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 92. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 93. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 98. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGING THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 99. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 100. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 101. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 102. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 103. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
  • TABLE 104. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 105. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 106. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 109. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 110. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 111. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGING THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 112. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 113. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 114. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 115. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
  • TABLE 117. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 118. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 119. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 123. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 124. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGING THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 125. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 126. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 127. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 128. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
  • TABLE 130. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 131. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 132. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGING THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 148. AUSTRALIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 149. AUSTRALIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 150. AUSTRALIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 151. AUSTRALIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 152. AUSTRALIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGING THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 153. AUSTRALIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 154. AUSTRALIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 155. AUSTRALIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 156. AUSTRALIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 157. AUSTRALIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
  • TABLE 158. AUSTRALIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 159. AUSTRALIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 160. AUSTRALIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 161. CHINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 162. CHINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 163. CHINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 164. CHINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 165. CHINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGING THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 166. CHINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 167. CHINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 168. CHINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 169. CHINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. CHINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
  • TABLE 171. CHINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 172. CHINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 173. CHINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. INDIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 175. INDIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 176. INDIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 177. INDIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 178. INDIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGING THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 179. INDIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 180. INDIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 181. INDIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 182. INDIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. INDIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
  • TABLE 184. INDIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 185. INDIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 186. INDIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. INDONESIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 188. INDONESIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 189. INDONESIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 190. INDONESIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 191. INDONESIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGING THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 192. INDONESIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 193. INDONESIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 194. INDONESIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 195. INDONESIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 196. INDONESIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
  • TABLE 197. INDONESIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 198. INDONESIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 199. INDONESIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 200. JAPAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 201. JAPAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 202. JAPAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 203. JAPAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 204. JAPAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGING THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 205. JAPAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 206. JAPAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 207. JAPAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 208. JAPAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 209. JAPAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
  • TABLE 210. JAPAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 211. JAPAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 212. JAPAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 213. MALAYSIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 214. MALAYSIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 215. MALAYSIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 216. MALAYSIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 217. MALAYSIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGING THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 218. MALAYSIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 219. MALAYSIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 220. MALAYSIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 221. MALAYSIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 222. MALAYSIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
  • TABLE 223. MALAYSIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 224. MALAYSIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 225. MALAYSIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 226. PHILIPPINES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 227. PHILIPPINES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 228. PHILIPPINES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 229. PHILIPPINES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 230. PHILIPPINES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGING THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 231. PHILIPPINES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 232. PHILIPPINES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 233. PHILIPPINES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 234. PHILIPPINES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 235. PHILIPPINES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
  • TABLE 236. PHILIPPINES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 237. PHILIPPINES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 238. PHILIPPINES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 239. SINGAPORE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 240. SINGAPORE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 241. SINGAPORE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 242. SINGAPORE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 243. SINGAPORE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGING THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 244. SINGAPORE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 245. SINGAPORE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 246. SINGAPORE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 247. SINGAPORE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 248. SINGAPORE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
  • TABLE 249. SINGAPORE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 250. SINGAPORE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 251. SINGAPORE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 252. SOUTH KOREA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 253. SOUTH KOREA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 254. SOUTH KOREA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 255. SOUTH KOREA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 256. SOUTH KOREA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGING THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 257. SOUTH KOREA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 258. SOUTH KOREA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 259. SOUTH KOREA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 260. SOUTH KOREA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 261. SOUTH KOREA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
  • TABLE 262. SOUTH KOREA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 263. SOUTH KOREA ALZHEIMER'S DISEASE DIAGNO